Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines - Antithrombotic therapy and prevention of thrombosis, 9th ed

American College of Chest Physicians evidence-based clinical practice guidelines

Gordon H. Guyatt, Susan L. Norris, Sam Schulman, Jack Hirsh, Mark H. Eckman, Elie A. Akl, Mark Crowther, Per Olav Vandvik, John W. Eikelboom, Marian McDonagh, Sandra Zelman Lewis, David D. Gutterman, Deborah J. Cook, Holger J. Schünemann

Research output: Contribution to journalArticle

175 Citations (Scopus)

Abstract

Background: To develop the Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: ACCP Evidence-Based Clinical Practice Guidelines (AT9), the American College of Chest Physicians (ACCP) assembled a panel of clinical experts, information scientists, decision scientists, and systematic review and guideline methodologists. Methods: Clinical areas were designated as articles, and a methodologist without important intellectual or financial conflicts of interest led a panel for each article. Only panel members without significant conflicts of interest participated in making recommendations. Panelists specified the population, intervention and alternative, and outcomes for each clinical question and defined criteria for eligible studies. Panelists and an independent evidence-based practice center executed systematic searches for relevant studies and evaluated the evidence, and where resources and evidence permitted, they created standardized tables that present the quality of the evidence and key results in a transparent fashion. Results:One or more recommendations relate to each specific clinical question, and each recommendation is clearly linked to the underlying body of evidence. Judgments regarding the quality of evidence and strength of recommendations were based on approaches developed by the Grades of Recommendations, Assessment, Development, and Evaluation Working Group. Panel members constructed scenarios describing relevant health states and rated the disutility associated with these states based on an additional systematic review of evidence regarding patient values and preferences for antithrombotic therapy. These ratings guided value and preference decisions underlying the recommendations. Each topic panel identified questions in which resource allocation issues were particularly important and, for these issues, experts in economic analysis provided additional searches and guidance. Conclusions: AT9 methodology reflects the current science of evidence-based clinical practice guideline development, with reliance on high-quality systematic reviews, a standardized process for quality assessment of individual studies and the body of evidence, an explicit process for translating the evidence into recommendations, disclosure of financial as well as intellectual conflicts of interest followed by management of disclosed conflicts, and extensive peer review.

Original languageEnglish (US)
JournalChest
Volume141
Issue number2 SUPPL.
DOIs
StatePublished - Feb 2012

Fingerprint

Conflict of Interest
Evidence-Based Practice
Practice Guidelines
Thrombosis
Guidelines
Peer Review
Process Assessment (Health Care)
Resource Allocation
Patient Preference
Disclosure
Thorax
Therapeutics
Economics
Physicians
Health
Population

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines - Antithrombotic therapy and prevention of thrombosis, 9th ed : American College of Chest Physicians evidence-based clinical practice guidelines. / Guyatt, Gordon H.; Norris, Susan L.; Schulman, Sam; Hirsh, Jack; Eckman, Mark H.; Akl, Elie A.; Crowther, Mark; Vandvik, Per Olav; Eikelboom, John W.; McDonagh, Marian; Lewis, Sandra Zelman; Gutterman, David D.; Cook, Deborah J.; Schünemann, Holger J.

In: Chest, Vol. 141, No. 2 SUPPL., 02.2012.

Research output: Contribution to journalArticle

Guyatt, GH, Norris, SL, Schulman, S, Hirsh, J, Eckman, MH, Akl, EA, Crowther, M, Vandvik, PO, Eikelboom, JW, McDonagh, M, Lewis, SZ, Gutterman, DD, Cook, DJ & Schünemann, HJ 2012, 'Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines - Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines', Chest, vol. 141, no. 2 SUPPL.. https://doi.org/10.1378/chest.11-2288
Guyatt, Gordon H. ; Norris, Susan L. ; Schulman, Sam ; Hirsh, Jack ; Eckman, Mark H. ; Akl, Elie A. ; Crowther, Mark ; Vandvik, Per Olav ; Eikelboom, John W. ; McDonagh, Marian ; Lewis, Sandra Zelman ; Gutterman, David D. ; Cook, Deborah J. ; Schünemann, Holger J. / Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines - Antithrombotic therapy and prevention of thrombosis, 9th ed : American College of Chest Physicians evidence-based clinical practice guidelines. In: Chest. 2012 ; Vol. 141, No. 2 SUPPL.
@article{99e6ecb509274e9fa523a45d5bc23653,
title = "Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines - Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines",
abstract = "Background: To develop the Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: ACCP Evidence-Based Clinical Practice Guidelines (AT9), the American College of Chest Physicians (ACCP) assembled a panel of clinical experts, information scientists, decision scientists, and systematic review and guideline methodologists. Methods: Clinical areas were designated as articles, and a methodologist without important intellectual or financial conflicts of interest led a panel for each article. Only panel members without significant conflicts of interest participated in making recommendations. Panelists specified the population, intervention and alternative, and outcomes for each clinical question and defined criteria for eligible studies. Panelists and an independent evidence-based practice center executed systematic searches for relevant studies and evaluated the evidence, and where resources and evidence permitted, they created standardized tables that present the quality of the evidence and key results in a transparent fashion. Results:One or more recommendations relate to each specific clinical question, and each recommendation is clearly linked to the underlying body of evidence. Judgments regarding the quality of evidence and strength of recommendations were based on approaches developed by the Grades of Recommendations, Assessment, Development, and Evaluation Working Group. Panel members constructed scenarios describing relevant health states and rated the disutility associated with these states based on an additional systematic review of evidence regarding patient values and preferences for antithrombotic therapy. These ratings guided value and preference decisions underlying the recommendations. Each topic panel identified questions in which resource allocation issues were particularly important and, for these issues, experts in economic analysis provided additional searches and guidance. Conclusions: AT9 methodology reflects the current science of evidence-based clinical practice guideline development, with reliance on high-quality systematic reviews, a standardized process for quality assessment of individual studies and the body of evidence, an explicit process for translating the evidence into recommendations, disclosure of financial as well as intellectual conflicts of interest followed by management of disclosed conflicts, and extensive peer review.",
author = "Guyatt, {Gordon H.} and Norris, {Susan L.} and Sam Schulman and Jack Hirsh and Eckman, {Mark H.} and Akl, {Elie A.} and Mark Crowther and Vandvik, {Per Olav} and Eikelboom, {John W.} and Marian McDonagh and Lewis, {Sandra Zelman} and Gutterman, {David D.} and Cook, {Deborah J.} and Sch{\"u}nemann, {Holger J.}",
year = "2012",
month = "2",
doi = "10.1378/chest.11-2288",
language = "English (US)",
volume = "141",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "2 SUPPL.",

}

TY - JOUR

T1 - Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines - Antithrombotic therapy and prevention of thrombosis, 9th ed

T2 - American College of Chest Physicians evidence-based clinical practice guidelines

AU - Guyatt, Gordon H.

AU - Norris, Susan L.

AU - Schulman, Sam

AU - Hirsh, Jack

AU - Eckman, Mark H.

AU - Akl, Elie A.

AU - Crowther, Mark

AU - Vandvik, Per Olav

AU - Eikelboom, John W.

AU - McDonagh, Marian

AU - Lewis, Sandra Zelman

AU - Gutterman, David D.

AU - Cook, Deborah J.

AU - Schünemann, Holger J.

PY - 2012/2

Y1 - 2012/2

N2 - Background: To develop the Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: ACCP Evidence-Based Clinical Practice Guidelines (AT9), the American College of Chest Physicians (ACCP) assembled a panel of clinical experts, information scientists, decision scientists, and systematic review and guideline methodologists. Methods: Clinical areas were designated as articles, and a methodologist without important intellectual or financial conflicts of interest led a panel for each article. Only panel members without significant conflicts of interest participated in making recommendations. Panelists specified the population, intervention and alternative, and outcomes for each clinical question and defined criteria for eligible studies. Panelists and an independent evidence-based practice center executed systematic searches for relevant studies and evaluated the evidence, and where resources and evidence permitted, they created standardized tables that present the quality of the evidence and key results in a transparent fashion. Results:One or more recommendations relate to each specific clinical question, and each recommendation is clearly linked to the underlying body of evidence. Judgments regarding the quality of evidence and strength of recommendations were based on approaches developed by the Grades of Recommendations, Assessment, Development, and Evaluation Working Group. Panel members constructed scenarios describing relevant health states and rated the disutility associated with these states based on an additional systematic review of evidence regarding patient values and preferences for antithrombotic therapy. These ratings guided value and preference decisions underlying the recommendations. Each topic panel identified questions in which resource allocation issues were particularly important and, for these issues, experts in economic analysis provided additional searches and guidance. Conclusions: AT9 methodology reflects the current science of evidence-based clinical practice guideline development, with reliance on high-quality systematic reviews, a standardized process for quality assessment of individual studies and the body of evidence, an explicit process for translating the evidence into recommendations, disclosure of financial as well as intellectual conflicts of interest followed by management of disclosed conflicts, and extensive peer review.

AB - Background: To develop the Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: ACCP Evidence-Based Clinical Practice Guidelines (AT9), the American College of Chest Physicians (ACCP) assembled a panel of clinical experts, information scientists, decision scientists, and systematic review and guideline methodologists. Methods: Clinical areas were designated as articles, and a methodologist without important intellectual or financial conflicts of interest led a panel for each article. Only panel members without significant conflicts of interest participated in making recommendations. Panelists specified the population, intervention and alternative, and outcomes for each clinical question and defined criteria for eligible studies. Panelists and an independent evidence-based practice center executed systematic searches for relevant studies and evaluated the evidence, and where resources and evidence permitted, they created standardized tables that present the quality of the evidence and key results in a transparent fashion. Results:One or more recommendations relate to each specific clinical question, and each recommendation is clearly linked to the underlying body of evidence. Judgments regarding the quality of evidence and strength of recommendations were based on approaches developed by the Grades of Recommendations, Assessment, Development, and Evaluation Working Group. Panel members constructed scenarios describing relevant health states and rated the disutility associated with these states based on an additional systematic review of evidence regarding patient values and preferences for antithrombotic therapy. These ratings guided value and preference decisions underlying the recommendations. Each topic panel identified questions in which resource allocation issues were particularly important and, for these issues, experts in economic analysis provided additional searches and guidance. Conclusions: AT9 methodology reflects the current science of evidence-based clinical practice guideline development, with reliance on high-quality systematic reviews, a standardized process for quality assessment of individual studies and the body of evidence, an explicit process for translating the evidence into recommendations, disclosure of financial as well as intellectual conflicts of interest followed by management of disclosed conflicts, and extensive peer review.

UR - http://www.scopus.com/inward/record.url?scp=84856705100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856705100&partnerID=8YFLogxK

U2 - 10.1378/chest.11-2288

DO - 10.1378/chest.11-2288

M3 - Article

VL - 141

JO - Chest

JF - Chest

SN - 0012-3692

IS - 2 SUPPL.

ER -